Drug intelligence / Profile preview

ORIC-944 + darolutamide

Development stage: Unknown
Lead developer: ORIC Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

A combination therapy consisting of **ORIC-944**, a potent and selective allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the embryonic ectoderm development (EED) subunit, and **darolutamide**, an androgen receptor inhibitor marketed as Nubeqa. This combination is under investigation for the treatment of metastatic castration-resistant prostate cancer (mCRPC), particularly for patients previously treated with androgen receptor pathway inhibitors and up to one prior chemotherapy. Early clinical trials demonstrate substantial clinical activity (high PSA50 and PSA90 response rates) and a favorable safety profile, predominantly mild to moderate gastrointestinal side effects.[1][2][3][4][5]

Brand names: Nubeqa
Other names: ORIC-944 + Nubeqa

Targets

EED (Embryonic ectoderm development protein)AR (Adrenergic receptors)

Beyond the preview

Go deeper on ORIC-944 + darolutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORIC-944 + darolutamide.

Explore the full profile